Disabled-2 heterozygous mice are predisposed to endometrial and ovarian tumorigenesis and exhibit sex-biased embryonic lethality in a p53-Null background

American Journal of Pathology

Volumn 169, Issue 1, 2006, Pages 258-267

  Yang, Dong Hua ^a   Fazili, Zia ^a,b,c   Smith, Elizabeth R ^a   Cai, Kathy Qi ^a   Klein Szanto, Andres ^a   Cohen, Cynthia ^b   Horowitz, Ira R ^b   Xu, Xiang Xi ^a,d  

^a FOX CHASE CANCER CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAB2 PROTEIN; DISABLED 2 PROTEIN; DNA; PHOSPHOPROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; ENDOMETRIUM TUMOR; FEMALE; HISTOCHEMISTRY; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERPLASIA; KNOCKOUT MOUSE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY TUMOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UTERUS TUMOR; WESTERN BLOTTING;

EID: 33745686462     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.060036     Document Type: Article

References (47)

1. Xu XX, Yang W, Jackowski S, Rock CO: Cloning of a novel phosphoprotein regulated by colony-stimulating factor 1 shares a domain with the Drosophila disabled gene product. J Biol Chem 1995, 270:14184-14191
2. Mok SC, Wong KK, Chan RK, Lau CC, Tsao SW, Knapp RC, Berkowitz RS: Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gynecol Oncol 1994, 52:247-252
3. Fazili Z, Sun W, Mittelstaedt S, Cohen C, Xu XX: Loss of Disabled-2 is an early step in ovarian tumorigenicity. Oncogene 1999, 18:3104-3113
4. Mok SC, Chan WY, Wong KK, Cheung KK, Lau CC, Ng SW, Baldini A, Colitti CV, Rock CO, Berkowitz RS: DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer. Oncogene 1998, 16:2381-2387
5. Sheng Z, Sun W, Smith ER, Cohen C, Sheng Z, Xu XX: Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells. Oncogene 2000, 19:4847-4854
6. He J, Smith ER, Xu XX: Disabled-2 exerts its tumor suppressor activity by uncoupling c-Fos expression and MAP kinase activation. J Biol Chem 2001, 276:26814-26818
7. Smith ER, Capo-Chichi CD, He J, Smedberg JL, Yang DH, Prowse AH, Godwin AK, Hamilton TC, Xu XX: Disabled-2 mediates c-Fos suppression and the cell growth regulatory activity of retinoic acid in embryonic carcinoma cells. J Biol Chem 2001, 276:47303-47310
8. Schwahn DJ, Medina D: p96, a MAPK-related protein, is consistently downregulated during mouse mammary carcinogenesis. Oncogene 1998, 17:1173-1178
9. Fulop V, Colitti CV, Genest D, Berkowitz RS, Yiu GK, Ng SW, Szepesi J, Mok SC: DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases. Oncogene 1998, 17:419-424
10. Tseng CP, Ely BD, Li Y, Pong RC, Hsieh JT: Regulation of rat DOC-2 gene during castration-induced rat ventral prostatic degeneration and its growth inhibitory function in human prostatic carcinoma cells. Endocrinology 1998, 139:3542-3553
11. Morris SM, Cooper JA: Disabled-2 colocalizes with the LDLR in clathrin-coated pits and interacts with AP-2. Traffic 2001, 2:111-123
12. Mishra SK, Keyel PA, Hawryluk MJ, Agostinelli NR, Watkins SC, Traub LM: Disabled-2 exhibits the properties of a cargo-selective endocytic clathrin adaptor. EMBO J 2002, 21:4915-4926
13. Inoue A, Sato O, Homma K, Ikebe M: DOC-2/DAB2 is the binding partner of myosin VI. Biochem Biophys Res Commun 2002, 292:300-307
14. Morris SM, Arden SD, Roberts RC, Kendrick-Jones J, Cooper JA, Luzio JP, Buss F: Myosin VI binds to and localizes with Dab2, potentially linking receptor-mediated endocytosis and the actin cytoskeleton. Traffic 2002, 3:331-341
15. Oleinikov AV, Zhao J, Makker SP: Cytosolic adaptor protein Dab2 is an intracellular ligand of endocytic receptor gp600/megalin. Biochem J 2000, 347:613-621
16. Trommsdorff M, Gotthardt M, Hiesberger T, Shelton J, Stockinger W, Nimpf J, Hammer RE, Richardson JA, Herz J: Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell 1999, 97:689-701
17. Howell BW, Lanier LM, Frank R, Gertler FB, Cooper JA: The disabled 1 phosphotyrosine-binding domain binds to the internalization signals of transmembrane glycoproteins and to phospholipids. Mol Cell Biol 1999, 19:5179-5188
18. Hocevar BA, Prunier C, Howe PH: Disabled-2 (Dab2) mediates transforming growth factor beta (TGFbeta)-stimulated fibronectin synthesis through TGFbeta-activated kinase 1 and activation of the JNK pathway. J Biol Chem 2005, 280:25920-25927
19. Hocevar BA, Smine A, Xu XX, Howe PH: The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway. EMBO J 2001, 20:2789-2801
20. Zhou J, Hsieh JT: The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade. DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2. J Biol Chem 2001, 276:27793-27798
21. Morris SM, Tallquist MD, Rock CO, Cooper JA: Dual roles for the Dab2 adaptor protein in embryonic development and kidney transport. EMBO J 2002, 21:1555-1564
22. Yang DH, Smith ER, Roland IH, Sheng Z, He J, Martin WD, Hamilton TC, Lambeth JD, Xu XX: Disabled-2 is essential for endodermal cell positioning and structure formation during early extraembryonic development. Dev Biol 2002, 251:27-44
23. Yang DH, Smith ER, Cohen C, Patriotis C, Godwin AK, Hamilton TC, Xu XX: Molecular events associated with dysplastic morphological transformation and initiation of ovarian tumorigenicity. Cancer 2002, 94:2380-2392
24. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu XX, Hamilton TC: Focus on epithelial ovarian cancer. Cancer Cell 2004, 5:19-24
25. Bell DA: Origins and molecular pathology of ovarian cancer. Mod Pathol 2005, 18(Suppl 2):S19-S32
26. Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast Jr RC: The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 1994, 170:246-252
27. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA: Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994, 4:1-7
28. Chen CM, Chang JL, Behringer RR: Tumor formation in p53 mutant ovaries transplanted into wild-type female hosts. Oncogene 2004, 23:7722-7725
29. Flesken-Nikitin A, Choi KC, Eng JP, Shmidt EN, Nikitin AY: Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 2003, 63:3459-3463
30. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T: Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005, 11:63-70
31. Silverberg S, Kurman R, Nogales F, Mutter G, Kubik-Huch R, Tavasoli F: Epithelial tumours and related lesions. Tumours of the breast and female genital organs. WHO Classification of Tumours. Edited by Tavasoli F, Devilee P. Lyon, IARC Press, 2003, pp 217-230
32. Scully RE: Pathology of ovarian cancer precursors. J Cell Biochem Suppl 1995, 23:208-218
33. Aoki Y, Kawada N, Tanaka K: Early form of ovarian cancer originating in inclusion cysts. A case report. J Reprod Med 2000, 45:159-161
34. Feeley KM, Wells M: Precursor lesions of ovarian epithelial malignancy. Histopathology 2001, 38:87-95
35. Resta L, Russo S, Colucci GA, Prat J: Morphologic precursors of ovarian epithelial tumors. Obstet Gynecol 1993, 82:181-186
36. Berchuck A, Boyd J: Molecular basis of endometrial cancer. Cancer 1995, 76:2034-2040
37. Jonkers J, Berns A: Conditional mouse models of sporadic cancer. Nat Rev Cancer 2002, 2:251-265
38. Cranston A, Bocker T, Reitmair A, Palazzo J, Wilson T, Mak T, Fishel R: Female embryonic lethality in mice nullizygous for both Msh2 and p53. Nat Genet 1997, 17:114-118
39. Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW: High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res 2000, 60:3605-3611
40. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, Cordon-Cardo C, Catoretti G, Fisher PE, Parsons R: Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999, 96:1563-1568
41. Clark Jr WH: The nature of cancer: morphogenesis and progressive (self)-disorganization in neoplastic development and progression. Acta Oncol 1995, 34:3-21
42. Klezovitch O, Fernandez TE, Tapscott SJ, Vasioukhin V: Loss of cell polarity causes severe brain dysplasia in Lgl1 knockout mice. Genes Dev 2004, 18:559-571
43. Baas AF, Kuipers J, van der Wel NN, Batlle E, Koerten HK, Peters PJ, Clevers HC: Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD. Cell 2004, 116:457-466
44. Baas AF, Smit L, Clevers H: LKB1 tumor suppressor protein: PAR-taker in cell polarity. Trends Cell Biol 2004, 14:312-319
45. Bardeesy N, Sinha M, Hezel AF, Signoretti S, Hathaway NA, Sharpless NE, Loda M, Carrasco DR, DePinho RA: Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature 2002, 419:162-167
46. Jishage K, Nezu J, Kawase Y, Iwata T, Watanabe M, Miyoshi A, Ose A, Habu K, Kake T, Kamada N, Ueda O, Kinoshita M, Jenne DE, Shimane M, Suzuki H: Role of Lkb1, the causative gene of Peutz-Jegher's syndrome, in embryogenesis and polyposis. Proc Natl Acad Sci USA 2002, 99:8903-8908
47. Miyoshi H, Nakau M, Ishikawa TO, Seldin MF, Oshima M, Taketo MM: Gastrointestinal hamartomatous polyposis in Lkb1 heterozygous knockout mice. Cancer Res 2002, 62:2261-2266